GALT (42) CTNM (40) SPRY (27) RLMD (44) ⌘ Pro Terminal →

Cypherpunk Technologies Inc. (CYPH) — RQD Stock Rating Cockpit

$3.31 +2.16% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.32

Cypherpunk Technologies Inc. (CYPH) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $356.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.32 (+0.20%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-8.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CYPH)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (40/100 Composite)

🔍 WHY CYPH SCORES 40/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+12/20 pts (30% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+11/20 pts (28% of score)

FRED Regime × Technicals: 77% of 52W Range • RSI-14 at 51 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$2.94-12.6% Next Q

Q2 (-2Q)

Grade E$2.57+9.7% Next Q

Q3 (-1Q)

Grade E$2.82+17.4% Next Q

Current

Grade D-$3.31-7.4% Hist 90D α

Trajectory: E (32) → D- (40)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CYPH Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CYPH currently carries a cautious 40/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.74) and Max Pain ($3.48) forces dealer call-delta covering toward $4.40.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CYPH• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CYPH Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 40%NO 60%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

5130 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

3 / 99-Pt Accounting

52-WEEK LASER RANGE77% OF RANGE

L: $0$3.31H: $4

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 4 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 15 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D+RQD 21 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on CYPH

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (20)

-23.3% ROIC with 42.0% gross margin and -12.31% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (50)

Altman-Z 4.20 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (43)

15/40 institutional & smart-money positioning score with 11/20 macro alignment.

Bull Case: Why Buyers Like CYPH

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Priced at 71x earnings—high expectations leave less room for a lukewarm quarter.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CYPH)

✓Walkthrough of CYPH's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CYPH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +271.91%▲ ASCENDING CHANNEL

2026-10-30O $2.96H $3.31L $2.75C $3.31VOL 14.27M

RES: $4.93SUP: $0.77SMA50: $2.74SMA200: $1.28

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CYPH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CYPH Butterfly Map → + Track CYPH →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

46.4%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CYPH today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CYPH. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CYPH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CYPH)

Health Care Rank #638 of 1016 ⚔️ GALT vs CYPH Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CYPH vs. GALT, CTNM, SPRY, RLMD)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Cypherpunk Technologies Inc. (CYPH) ranks #638 by composite RQD confidence (40/100, grade D-) and #498 by equity capitalization ($356.7M). Within this direct 5-issuer industry benchmark cohort, CYPH leads on earnings valuation at 71.3x trailing P/E, while CYPH leads on capital efficiency and profitability with -23.3% ROIC and — gross margin. RLMD currently holds the highest overall quantitative score in the immediate peer group at 44/100 (D) compared with CYPH at 40/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CYPH ACTIVE Cypherpunk Technologies Inc.	D-	40/100	71.3x	—	-23.3%	+2.16%	$356.7M	Benchmark Subject
GALT Galectin Therapeutics Inc.	D-	42/100	—	—	-35.0%	-0.56%	$355.8M	/galt-vs-cyph →
CTNM Contineum Therapeutics Inc. (Class A)	D-	40/100	—	—	-29.0%	+1.97%	$351.0M	/ctnm-vs-cyph →
SPRY ARS Pharmaceuticals Inc.	E	27/100	—	—	-35.0%	+0.27%	$364.0M	/spry-vs-cyph →
RLMD Relmada Therapeutics Inc.	D	44/100	—	—	-35.0%	+2.69%	$366.9M	/rlmd-vs-cyph →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001509745

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cypherpunk Technologies Inc. (CYPH) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of $5.0M, operating cash flow of -$43.9M, and free cash flow of -$43.9M (+27.2% YoY). On the balance sheet, CYPH closed FY2025 with $163.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$5.0M	-$43.9M	-$43.9M	$163.2M	—
FY2024 (FY)	2024-12-31	$0	-$68.0M	-$60.3M	-$60.3M	$49.1M	—
FY2023 (FY)	2023-12-31	$0	-$81.0M	-$43.8M	-$43.8M	—	—

3. CYPH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CYPH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Cypherpunk Technologies Inc. (NASDAQ: CYPH) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $3.31 (+2.16% 1D, market cap $356.7M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CYPH ranks #638 in composite RQD confidence.

How does CYPH compare to GALT and CTNM in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CYPH carries a Roarable D- (40/100 RQD), trailing P/E of 71.3x, gross margin of —, and ROIC of -23.3%. By comparison, GALT (Galectin Therapeutics Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $355.8M) and CTNM (Contineum Therapeutics Inc. (Class A)) posts a D- grade (40/100 RQD, P/E N/A, ROIC -29.0%, cap $351.0M). Among the 5-stock peer group, CYPH leads on earnings multiple (71.3x) while CYPH leads on capital efficiency (-23.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CYPH?

Per CYPH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001509745), Cypherpunk Technologies Inc. generated $0 in revenue, $5.0M in net income, and -$43.9M in free cash flow against $163.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CYPH trading relative to its 50-day, 200-day, and 52-week technical levels?

CYPH last traded at $3.31 (+2.16% on volume of 18,780,567 shares), positioning the stock +20.80% above its 50-day simple moving average ($2.74) and +158.59% above its 200-day simple moving average ($1.28). Across its 52-week range of $0.39 to $4.19, CYPH sits at the 76.8% percentile with a 14-day RSI of 51.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.90 to $3.72).

CYPH Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell CYPH stock right now?

Cypherpunk Technologies Inc. (CYPH) currently earns a Roarable Rating of D- (Sell — SELL) with 40/100 RQD Confidence. Stretched risk/reward at 71x P/E (-23% return on capital) under elevated 10-year interest-rate pressure.

What is CYPH's 12-month price target and RQD AI Jury consensus?

CYPH's 12-month base price target is $3.04 (range $2.37 to $4.4), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: CYPH RQD Cockpit CYPH 12M Forecast CYPH Earnings & Move CYPH Dividends & DRIP CYPH Insiders & 13F CYPH Whale Options CYPH Profit Sankey CYPH News & Why